Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for warfarin (compound)


PubChem
Name: Warfarin
PubChem Compound ID: 447632
Description: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Molecular formula: C19H16O4
Molecular weight: 308.328 g/mol
Synonyms:
4-HYDROXY-3-[(1S)-3-OXO-1-PHENYLBUTYL]-2H-CHROMEN-2-ONE; SWF; S-WARFARIN; ZINC00044634
DrugBank
Identification
Name: Warfarin
Name (isomeric): DB00682
Drug Type: small molecule
Description: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Synonyms:
Warfarin sodium
Brand: Dicusat E, Rosex, Tintorane, Kumadu, Kypfarin, D-Con, Warfarin Q, Dethmor, Frass-Ratron, Brumolin, Vampirinip III, Co-Rax, Temus W, Warf 42, Sofarin, Athrombin, Coumarins, Prothromadin, Place-Pax, Dethnel, Athrombin-K, Kumatox, Warficide, Coumaphene, RAX, Marevan, Solfarin, Coumadin Tabs, Coumadin, Athrombine-K, Warfilone, Coumefene, Coumafene, Jantoven, Kumader, Coumaphen, Tox-Hid, Panwarfin, Warfarat, Maveran, Latka 42, Warfarin Plus, Sorexa Plus, Vampirinip II, Warfarine, Zoocoumarin, Mar-Frin, Coumafen
Category: Rodenticides, Anticoagulants, Coumarin and Indandione Derivatives
CAS number: 81-81-2
Pharmacology
Indication: For the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.
Pharmacology: Warfarin, a coumarin anticoagulant, is a racemic mixture of two active isomers. It is used in the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).
Mechanism of Action:
Warfarin inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. T...
show more »
Absorption: Rapidly absorbed following oral administration with considerable interindividual variations. Also absorbed percutaneously.
Protein binding: 99% bound primarily to albumin
Biotransformation: Metabolized stereo- and regio-selectively by hepatic microsomal enzymes. S-warfarin is predominantly metabolized by cytochrome P450 (CYP) 2C9 to yield the 6- and 7-hydroxylated metabolites. R-warfarin is metabolized by CYP1A1, 1A2, and 3A4 to yield 6-, 8-, and 10-hydroxylated metabolites. Hydroxylated metabolites may be further conjugated prior to excretion into bile and urine. UGT1A1 appears to be responsible for producing the 6-O-glucuronide of warfarin, with a possibly contribution from UGT1A10. Five UGT1As may be involved in the formation of 7-O-glucuronide warfarin. S-warfarin has higher potency than R-warfarin and genetic polymorphisms in CYP2C9 may dramatically decrease clearance of and increase toxicity of the medication.
Route of elimination: The elimination of warfarin is almost entirely by metabolism. Very little warfarin is excreted unchanged in urine. The metabolites are principally excreted into the urine; and to a lesser extent into the bile.
Half Life: R-warfarin t1/2=37-89 hours; S-warfarin t1/2=21-43 hours.
Clearance: 0.065 +/- 0.025 mL/min/kg [CYP2C9 Genotype *1/*1] 0.041 +/- 0.021 [CYP2C9 Genotype *1/*2 or *1/*3] 0.020 +/- 0.011 [CYP2C9 Genotype *2/*2, *2/*3, or *3/*3]
Toxicity: LD50=374 (orally in mice)
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Consult your doctor before ingesting large amounts of dietary Vitamin K (e.g. from green leafy vegetables).
Avoid alcohol.
Limit garlic, ginger, gingko, and horse chestnut.
Avoid St. John's Wort.
Avoid drastic changes in dietary habit.
Drug interaction:
OfloxacinThe quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin.
ThiopentalThiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed.
Nandrolone decanoateNandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed.
Aminosalicylic AcidThe antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin.
PentoxifyllinePentoxifylline may increase the anticoagulant effect of warfarin.
show more »

Targets


Enzymes


Carriers